A lipoprotein fractionation test gives a closer look at the particles that carry cholesterol and triglycerides through the blood. A standard lipid panel reports total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Fractionation goes further by separating lipoproteins into classes such as LDL, HDL, VLDL, and IDL, and in some methods, into smaller subclasses by size, density, or particle number. This can be helpful when a person’s usual cholesterol numbers do not fully match their cardiovascular risk.
The test is most often used in people with high triglycerides, insulin resistance, diabetes, metabolic syndrome, premature heart disease, strong family history, mixed cholesterol patterns, or unclear results from a regular lipid panel. It can show whether LDL particle number is high, whether small dense LDL is increased, whether remnant particles are present, or whether HDL particle patterns look unfavorable. Results should be interpreted with the full health picture, not as a stand-alone diagnosis.
- A lipoprotein fractionation test measures cholesterol-rich and triglyceride-rich particle groups, often including LDL, HDL, VLDL, IDL, and particle subclasses.
- High LDL particle number usually means more artery-exposing atherogenic particles, even when LDL cholesterol looks only mildly elevated.
- High VLDL, IDL, or remnant particles often points to triglyceride-rich lipoprotein buildup, commonly linked with insulin resistance, diabetes, obesity, fatty liver, alcohol use, or genetic lipid disorders.
- Fasting is often preferred, especially when triglycerides, VLDL, IDL, or remnants are being evaluated, although some lipid screening can be done nonfasting.
- Results vary by method, so LDL-P, HDL-P, particle size, and subclass ranges should be compared with the laboratory’s own reference intervals.
- Very high triglycerides, especially around 500 mg/dL or higher, need prompt medical follow-up because pancreatitis risk begins to rise.
Table of Contents
- What the Lipoprotein Fractionation Test Measures
- Why the Test Is Ordered
- How Lipoprotein Fractionation Works
- Understanding the Main Lipoprotein Fractions
- Particle Number, Particle Size, and Discordance
- How to Interpret Lipoprotein Fractionation Results
- Preparation, Timing, and Follow-Up
- Common Mistakes When Reading Results
What the Lipoprotein Fractionation Test Measures
A lipoprotein fractionation test measures the different “carriers” that move fat-like substances through blood. Cholesterol and triglycerides cannot travel freely in watery plasma, so the body packages them into lipoproteins. Each lipoprotein particle contains lipids on the inside and proteins, called apolipoproteins, on the surface.
A regular lipid panel estimates or measures how much cholesterol is carried in broad categories. Fractionation tries to separate those categories into more detailed groups. Depending on the laboratory method, the report may include:
- LDL cholesterol or LDL particle number
- HDL cholesterol or HDL particle number
- VLDL cholesterol or VLDL particles
- IDL cholesterol or IDL particles
- LDL size or pattern
- Small, medium, and large LDL particles
- Small, medium, and large HDL particles
- Remnant cholesterol or remnant-like particles
- Sometimes chylomicron or lipoprotein(a)-related information
The most important distinction is cholesterol mass versus particle number. LDL cholesterol, often written as LDL-C, describes how much cholesterol is inside LDL particles. LDL particle number, often written as LDL-P, estimates how many LDL particles are present. These can move together, but they do not always match.
For example, two people can both have LDL-C of 110 mg/dL. One may have fewer large LDL particles carrying more cholesterol per particle. The other may have many small cholesterol-poor LDL particles. The second person may have a higher LDL-P and a higher burden of artery-entering particles despite having the same LDL-C.
Lipoprotein fractionation is therefore not just a more complicated cholesterol test. It is a different way of looking at lipid transport. It can reveal patterns that are hidden when only total cholesterol, LDL-C, HDL-C, and triglycerides are reviewed.
Why the Test Is Ordered
Lipoprotein fractionation is usually ordered when standard cholesterol results do not answer enough clinical questions. It is not needed for every person. Many people can be screened, treated, and monitored well with a standard lipid panel, non-HDL cholesterol, and sometimes apolipoprotein B. Fractionation becomes more useful when the lipid pattern is complex.
A clinician may order it when a person has premature coronary artery disease, a strong family history of heart attack or stroke, high triglycerides, diabetes, insulin resistance, metabolic syndrome, fatty liver disease, chronic kidney disease, or persistently abnormal cholesterol despite treatment. It may also help when LDL-C appears acceptable but overall risk seems higher than expected.
One common reason is LDL-C and LDL-P discordance. This means the cholesterol amount inside LDL particles does not match the number of LDL particles. Discordance is common in people with high triglycerides, low HDL-C, abdominal obesity, insulin resistance, or type 2 diabetes. In these situations, LDL particles may carry less cholesterol each, so the LDL-C value can understate the number of LDL particles circulating in blood.
Another reason is suspected remnant lipoprotein excess. VLDL and IDL are triglyceride-rich or remnant particles related to triglyceride metabolism. When they remain elevated, they can contribute to atherosclerosis. A person with high triglycerides and modest LDL-C may still have a high atherogenic particle burden because of VLDL remnants, IDL, and other apoB-containing particles. Related markers such as remnant cholesterol and non-HDL cholesterol can also help show this pattern.
Fractionation may also be used when a clinician wants to evaluate the effect of lifestyle changes or lipid-lowering therapy beyond LDL-C. For example, weight loss, improved insulin sensitivity, reduced refined carbohydrate intake, and lower alcohol intake may reduce VLDL, small LDL particles, and triglyceride-rich remnants even before LDL-C changes dramatically.
It is less useful as a one-time curiosity test in a low-risk person with clearly normal standard lipids. Extra numbers can create confusion when they do not change care. The best use is targeted: answer a specific question that standard testing leaves open.
How Lipoprotein Fractionation Works
Lipoprotein fractionation separates particles based on physical or chemical features. Different laboratories use different technologies, so two reports may not look identical. This is one reason results should be compared with the reference interval from the same laboratory whenever possible.
NMR lipoprotein testing
Nuclear magnetic resonance, or NMR, estimates lipoprotein particle concentrations by analyzing signals from lipid methyl groups inside particles. NMR reports often include LDL-P, HDL-P, VLDL particle measures, average LDL size, and small LDL-P. Many advanced lipid reports that list LDL particle number in nmol/L use NMR-based methods.
NMR can be useful when LDL-C and LDL-P do not match. It can also show a pattern commonly seen with insulin resistance: high triglycerides, large VLDL particles, increased small LDL particles, lower HDL particle number, and smaller average LDL size.
Ion mobility and electrophoresis
Ion mobility separates particles by size after particles are placed in a gas phase and moved through an electric field. Some reports provide particle counts and size-based subclasses. Gel electrophoresis separates lipoproteins based on movement through a gel, often producing LDL patterns such as larger, more buoyant LDL versus smaller, denser LDL.
These methods can be helpful for identifying LDL size patterns, but particle size alone should not be treated as more important than the total number of atherogenic particles. A person can have mostly large LDL and still have high risk if LDL-P or apoB is high.
Ultracentrifugation and density-based methods
Older and specialized laboratory methods may separate lipoproteins by density. Ultracentrifugation can distinguish chylomicrons, VLDL, IDL, LDL, and HDL because these particles differ in density and composition. Density-based approaches are valuable in research and some specialized clinical settings, but they are more labor-intensive than routine testing.
Some labs historically used vertical auto profile testing or other fractionation systems to report VLDL, IDL, LDL subclasses, HDL subclasses, and lipoprotein(a)-related cholesterol. Availability varies by region and laboratory.
The method matters because each technique measures a slightly different feature. A test called “LDL particle number” is not the same thing as “small dense LDL cholesterol,” and “LDL pattern B” is not the same thing as apoB. The report name, units, and method should be reviewed before comparing results across time.
Understanding the Main Lipoprotein Fractions
The major lipoprotein fractions represent different jobs in lipid transport. They also differ in how strongly they relate to atherosclerosis, triglyceride metabolism, and metabolic health.
| Fraction | Main role | Common concern when elevated or abnormal |
|---|---|---|
| LDL | Delivers cholesterol from liver-derived particles to tissues | Higher atherosclerotic cardiovascular risk when LDL-C, LDL-P, or apoB is high |
| HDL | Participates in reverse cholesterol transport and other protective functions | Low HDL-C or low HDL-P may reflect insulin resistance, inflammation, or higher cardiometabolic risk |
| VLDL | Carries triglycerides made by the liver | High VLDL often tracks with high triglycerides, fatty liver, insulin resistance, alcohol intake, or excess refined carbohydrates |
| IDL | Intermediate remnant formed as VLDL loses triglyceride | High IDL suggests remnant accumulation and can be atherogenic |
| Chylomicrons | Carry dietary triglycerides from the intestine after meals | Persistent fasting chylomicrons suggest severe triglyceride clearance problems |
| Lp(a) | LDL-like particle with apolipoprotein(a) | High levels are mostly genetic and can raise risk of atherosclerotic disease and aortic valve stenosis |
LDL is the best-known atherogenic fraction. LDL particles contain apolipoprotein B-100, and each LDL particle has one apoB molecule. LDL can enter the artery wall, become retained, undergo modification, and contribute to plaque formation. A high LDL-C remains an important treatment target, but LDL-P or ApoB testing can provide a closer estimate of particle burden when results are discordant.
HDL is often called “good cholesterol,” but that nickname oversimplifies it. HDL-C measures the cholesterol carried inside HDL particles. It does not directly measure HDL function. HDL particles participate in cholesterol transport, antioxidant activity, anti-inflammatory signaling, and other processes. Very low HDL-C often travels with high triglycerides and insulin resistance. Very high HDL-C is not automatically protective, especially when caused by genetics, alcohol excess, liver disease, or altered HDL function.
VLDL is made by the liver to export triglycerides. High VLDL usually appears when the liver is producing or releasing more triglyceride-rich particles. Common drivers include insulin resistance, excess calorie intake, high refined carbohydrate intake, alcohol, uncontrolled diabetes, hypothyroidism, kidney disease, certain medications, and genetic predisposition. A related result, VLDL cholesterol, is often estimated from triglycerides on a standard lipid panel, but fractionation may provide more detail.
IDL sits between VLDL and LDL in the metabolic pathway. As VLDL loses triglyceride through lipoprotein lipase activity, it becomes smaller and more cholesterol-enriched, forming IDL. Some IDL is cleared by the liver, and some is further processed into LDL. Elevated IDL cholesterol can suggest remnant particle accumulation, especially when triglycerides and total cholesterol are both elevated.
Chylomicrons are normally most prominent after meals. They carry dietary triglycerides from the intestine. In a fasting sample, significant chylomicron presence can point to severe hypertriglyceridemia or impaired triglyceride clearance. This matters because very high triglycerides can increase pancreatitis risk.
Lipoprotein(a), or Lp(a), is sometimes reported on advanced lipid testing, although it is a distinct marker rather than a standard fraction in every fractionation method. It resembles LDL but has an added apolipoprotein(a) component. Because Lp(a) is largely inherited, one well-performed adult measurement is often enough for risk assessment unless treatment or major health changes require reassessment.
Particle Number, Particle Size, and Discordance
Particle number often gives different information from cholesterol concentration. This difference is central to lipoprotein fractionation.
LDL-C measures the cholesterol inside LDL particles. LDL-P measures how many LDL particles are present. ApoB estimates the number of atherogenic particles because each LDL, VLDL, IDL, Lp(a), and chylomicron remnant particle generally carries one apoB molecule. When LDL-P or apoB is high, there are more particles capable of entering or interacting with the artery wall.
Discordance occurs when LDL-C and particle burden do not agree. A common pattern is normal or mildly high LDL-C with high LDL-P or apoB. This can happen when LDL particles are smaller and carry less cholesterol per particle. The total cholesterol inside LDL may look acceptable, but the number of particles may still be high.
This pattern often appears with:
- High triglycerides
- Low HDL-C
- Insulin resistance or high fasting insulin
- Type 2 diabetes
- Metabolic syndrome
- Abdominal obesity
- Fatty liver disease
- Chronic inflammation
- Some genetic combined lipid disorders
LDL particle size is also reported on many fractionation tests. Larger LDL particles are often called pattern A. Smaller, denser LDL particles are often called pattern B. Pattern B commonly appears with high triglycerides and insulin resistance. Small dense LDL may be more likely to enter the artery wall, remain in circulation longer, and undergo oxidation.
Still, particle size should be interpreted carefully. A small LDL pattern usually matters because it travels with a higher number of apoB-containing particles. If LDL-P or apoB is low, small LDL size by itself is usually less concerning than high particle number. In practice, the total atherogenic particle burden usually carries more weight than size alone.
HDL particle number can also be reported. HDL-P is not the same as HDL-C. A person can have a normal HDL-C with a low number of HDL particles or altered HDL subclasses. Low HDL-P may reflect insulin resistance or inflammation, but HDL results have not become treatment targets in the same way LDL-C, non-HDL-C, and apoB have. Current care usually focuses on lowering atherogenic particles rather than trying to raise HDL-C with medication.
A helpful way to think about the report is this: LDL-C tells how much cholesterol is being transported in LDL; LDL-P and apoB tell how many atherogenic delivery vehicles are on the road. More vehicles can mean more arterial exposure, even if each vehicle carries a smaller cholesterol load. For a detailed companion marker, LDL particle number is often the most directly comparable result.
How to Interpret Lipoprotein Fractionation Results
Lipoprotein fractionation results are best read in layers. First review standard lipid values, then particle burden, then remnant particles, then particle size and HDL patterns. A single abnormal subclass should not outweigh the broader pattern.
Common standard lipid reference points for adults include total cholesterol below 200 mg/dL, HDL-C of at least 40 mg/dL in men and at least 50 mg/dL in women, triglycerides below 150 mg/dL, and LDL-C targets that depend on cardiovascular risk. A person with established atherosclerotic cardiovascular disease, diabetes with risk factors, familial hypercholesterolemia, or very high calculated risk may need a much lower LDL-C than a low-risk person.
Advanced reports often use laboratory-specific categories. Many NMR-style reports classify LDL-P roughly as optimal below 1000 nmol/L, near or above optimal around 1000–1299 nmol/L, borderline high around 1300–1599 nmol/L, high around 1600–2000 nmol/L, and very high above 2000 nmol/L. These cutoffs are not universal, so the lab’s own ranges should guide interpretation.
HDL-P is often reported in micromoles per liter. Higher HDL-P is generally more favorable, while low HDL-P may appear with insulin resistance and higher cardiometabolic risk. Unlike LDL-P, HDL-P is not usually used as a medication target. It is better viewed as part of the metabolic pattern.
VLDL and IDL results need to be interpreted with triglycerides. High VLDL particles or VLDL cholesterol usually means the liver is exporting more triglyceride-rich lipoproteins. High IDL or remnants means partly processed triglyceride-rich particles are accumulating. These remnants are important because they contain cholesterol and can contribute to plaque formation.
| Pattern | Possible meaning | Common next step |
|---|---|---|
| High LDL-C and high LDL-P | High LDL cholesterol mass and high LDL particle burden | Assess overall risk and intensify LDL-lowering lifestyle or medication plan as appropriate |
| Normal LDL-C but high LDL-P | Discordance; many cholesterol-poor LDL particles | Check triglycerides, insulin resistance, diabetes status, waist circumference, apoB, and non-HDL-C |
| High triglycerides, high VLDL, small LDL | Atherogenic dyslipidemia pattern often linked with insulin resistance | Address weight, refined carbohydrates, alcohol, glucose control, thyroid status, and medications |
| High IDL or remnant particles | Impaired remnant clearance or overproduction of triglyceride-rich particles | Evaluate triglycerides, apoB, diabetes, kidney disease, liver disease, and possible genetic disorders |
| Low HDL-C with low HDL-P | Often reflects metabolic risk, inflammation, smoking, or high triglycerides | Focus on exercise, weight management, smoking cessation, glucose control, and lowering apoB particles |
| Very high triglycerides with chylomicrons | Severe triglyceride clearance problem | Prompt medical follow-up to reduce pancreatitis risk |
Results should also be compared with apoB and non-HDL-C when available. Non-HDL-C equals total cholesterol minus HDL-C. It includes cholesterol inside LDL, VLDL, IDL, remnants, and Lp(a). It is simple, inexpensive, and reliable in fasting or nonfasting samples. ApoB goes one step closer to particle number by estimating the count of atherogenic particles.
Triglycerides deserve special attention. Borderline or moderate elevations may signal metabolic risk. Levels around 500 mg/dL or higher deserve prompt attention because pancreatitis risk rises as triglycerides climb, especially at very high levels. Severe elevations can come from uncontrolled diabetes, heavy alcohol intake, genetic chylomicronemia syndromes, pregnancy, kidney disease, hypothyroidism, or medications such as estrogen therapy, corticosteroids, some antipsychotics, some HIV medicines, and certain beta blockers.
Fractionation results should never be interpreted as a diagnosis of blocked arteries. They estimate blood lipid-related risk and metabolism. A person’s actual cardiovascular risk also depends on age, blood pressure, smoking, diabetes, kidney function, inflammatory disease, family history, coronary artery calcium, prior cardiovascular events, and medication history.
Preparation, Timing, and Follow-Up
Fasting instructions depend on the reason for testing. For broad cholesterol screening, nonfasting lipid testing is often acceptable. For lipoprotein fractionation, fasting for 9 to 12 hours is commonly preferred, especially if triglycerides, VLDL, IDL, remnants, or chylomicrons are important parts of the question. A recent meal can raise triglyceride-rich particles and make some fractions harder to interpret.
Water is usually allowed during fasting. Alcohol should generally be avoided for at least 24 hours before the test, and longer if a person has a history of alcohol-sensitive triglycerides. A very high-fat meal the night before testing can also affect triglyceride-rich particles. Usual medications should not be stopped unless the ordering clinician gives specific instructions.
Timing matters after illness or major body changes. Acute infection, surgery, hospitalization, heart attack, major inflammation, pregnancy, rapid weight loss, and major diet changes can temporarily alter lipid results. Testing is often repeated after the person is stable if the result will guide long-term treatment.
If treatment is started or changed, repeat testing is often done after about 4 to 12 weeks, depending on the clinical situation and medication. Once results are stable, monitoring may occur every 3 to 12 months in higher-risk patients or less often in lower-risk patients. The best interval depends on risk level, treatment intensity, and whether results are changing.
Follow-up usually focuses on reducing atherogenic particles and improving triglyceride-rich lipoprotein metabolism. Depending on the pattern, this may include:
- Reducing saturated fat and replacing it with unsaturated fats when LDL-C or apoB is high
- Reducing refined starches, sugary drinks, and excess added sugars when triglycerides and VLDL are high
- Limiting or avoiding alcohol when triglycerides are elevated
- Increasing soluble fiber from oats, beans, lentils, psyllium, fruit, and vegetables
- Losing excess abdominal weight when insulin resistance is present
- Increasing aerobic and resistance exercise
- Improving blood glucose control in diabetes or prediabetes
- Treating hypothyroidism, kidney disease, or liver disease when present
- Reviewing medications that may raise triglycerides or worsen lipid patterns
- Using lipid-lowering medication when lifestyle changes are not enough or risk is high
Medication choices depend on the dominant problem. Statins, ezetimibe, PCSK9 inhibitors, inclisiran, and bempedoic acid mainly lower LDL-C and apoB-containing particles. Fibrates and prescription omega-3 therapies may be used in selected patients with high triglycerides, especially when pancreatitis prevention is a concern. The treatment plan should be based on cardiovascular risk, triglyceride level, other medical conditions, and medication safety.
Common Mistakes When Reading Results
The first common mistake is treating the fractionation report as separate from the standard lipid panel. The advanced report adds detail, but it does not erase the importance of LDL-C, non-HDL-C, triglycerides, and overall risk. A high-risk person may need aggressive LDL-lowering therapy even without exotic subclass abnormalities.
The second mistake is focusing too much on LDL size. Small dense LDL often signals insulin resistance and higher triglyceride-rich lipoprotein metabolism, but particle number usually deserves more attention. Large LDL particles can still be atherogenic when there are too many of them. Small LDL particles are most concerning when LDL-P, apoB, or non-HDL-C is also elevated. A companion review of LDL particle size can help separate pattern information from particle burden.
The third mistake is assuming high HDL-C cancels out high LDL or high apoB. HDL is biologically complex, and HDL-C is not a reliable shield against high atherogenic particle exposure. A person with high HDL-C and high LDL-P still needs proper risk assessment. Similarly, raising HDL-C with medication has not consistently reduced cardiovascular events when atherogenic particles remain high.
The fourth mistake is ignoring VLDL, IDL, and remnants because LDL gets most of the attention. Triglyceride-rich remnants are not harmless. They can carry cholesterol into the artery wall and often appear in people with insulin resistance, diabetes, obesity, kidney disease, and genetic lipid disorders. When triglycerides are high, the report should be read as a full apoB-particle pattern, not just an LDL report.
The fifth mistake is comparing results from different labs as if they are interchangeable. NMR, ion mobility, electrophoresis, and density-based methods can produce different subclass categories and units. If the purpose is monitoring, it is best to repeat the same type of test at the same laboratory when possible.
The sixth mistake is using one result to explain all cardiovascular risk. Lipoproteins are important, but they are one part of risk. Blood pressure, smoking, blood glucose, kidney function, inflammatory disease, family history, sleep, activity, diet quality, menopause status, and prior cardiovascular events also change risk. A fractionation test is most useful when it helps guide a broader prevention plan.
References
- Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group 2021 (Scientific Statement)
- Lipid Profile and Lipoprotein(a) Testing 2023 (Review)
- Lipoprotein assessment in the 21st century 2022 (Review)
- Review of Laboratory Methods to Determine HDL and LDL Subclasses and Their Clinical Importance 2022 (Review)
- Introduction to Lipids and Lipoproteins 2024 (Review)
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias 2025 (Guideline)
Disclaimer
Lipoprotein fractionation results should be interpreted by a qualified healthcare professional who can compare them with your medical history, medications, family history, and overall cardiovascular risk. Abnormal LDL-P, VLDL, IDL, remnant, or HDL particle results do not diagnose blocked arteries by themselves. Seek prompt medical care if triglycerides are very high, if you have symptoms of pancreatitis such as severe upper abdominal pain, or if you have chest pain, shortness of breath, weakness on one side, or other possible heart attack or stroke symptoms.
